Tag: Y-90

ebrahim s delpassand md facnm

FDA Approves Amendment for PRRT Clinical Trial in Texas

August 2, 2012

BREAKING NEWS:  The Food and Drug Administration (FDA) has just approved the RadioIsotope Therapy of America (RITA) Foundation’s amendment to the Investigational New Drug (IND) protocol for intra-hepatic artery administration of Lu-177 Octreotate

READ MORE
Multidisciplinary Team at Bad Berka

1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy (PRRNT)

April 5, 2011

Since 1997, when he first used the radiolabeled peptide Y-90 DOTATOC (a somatostatin analogue) to treat a 15-year-old boy with a rare neuroendocrine tumor, called paraganglioma, and saw the boy go from being wheelchair-bound and in terrible pain to …

READ MORE
ebrahim s delpassand md facnm

FDA Approves Novel Radio-peptide Targeted Therapy Clinical Trial for Neuroendocrine Cancer: PRRT (Peptide Receptor Radionuclide Therapy)

August 24, 2010

For the first time in North America, neuroendocrine cancer patients will have the opportunity to participate in a clinical trial of Lutetieum-177 (LU-177)with Octreotate. Ebrahim S. Delpassand, MD, chief executive officer and medical director of…

READ MORE
y 90 radiomicrosphere therapy workshop banner2

Y-90 Radiomicrosphere Therapy Workshop To Be Offered in Florida

May 12, 2010

Carcinoid and neuroendocrine cancer patients interested in learning more about Y-90 radiomicrosphere therapy can join physicians, scientists, and technologists for a workshop being presented by “Advances in Minimally Invasive Treatments” International

READ MORE